secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037578
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023
--------------------------------------------------------------------------------

- Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.
- Cash & equivalents $472M as of June 30, 2023; cash runway into second half of 2025.
- Partner Sanofi plans Phase 2 trials for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in Q4 2023.
- Phase 1 data for KT-253 (MDM2), KT-333 (STAT3), KT-413 (IRAKIMiD) expected later in 2023.
- Appointed Jeremy Chadwick as COO and Justine Koenigsberg as VP, Head of IR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/0000950170-23-037578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/kymr-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer